Lazarus Rochelle B - Jun 4, 2021 Form 4 Insider Report for Organon & Co. (OGN)

Role
Director
Signature
/s/ Faye C. Brown, as Attorney-in-Fact for Rochelle B. Lazarus
Stock symbol
OGN
Transactions as of
Jun 4, 2021
Transactions value $
$316,231
Form type
4
Date filed
6/8/2021, 08:33 PM
Previous filing
Jun 2, 2021
Next filing
Jul 13, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
holding OGN Common Stock 460 Jun 4, 2021 Direct F1
holding OGN Common Stock 175 Jun 4, 2021 By Spouse F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OGN Phantom Stock +Grant/Award $316,231 +8,772 $36.05 8,772 Jun 4, 2021 Common Stock 8,772 Direct F2, F3

Explanation of Responses:

Id Content
F1 Shares acquired in a pro rata distribution by Merck & Co., Inc. ("Merck") of shares of Organon & Co. ("Organon") in connection with the separation of Organon from Merck (the "Separation").
F2 1-for-1
F3 Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the Separation, which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases.